Last updated: February 27, 2026
What is the Scope and Focus of Patent KR20160002974?
Patent KR20160002974 covers a therapeutic antibody specifically designed to target PD-1 (Programmed Cell Death Protein 1). The patent claims primarily encompass the antibody composition, its methods of production, and uses in immunotherapy, particularly for cancers such as melanoma and non-small cell lung carcinoma (NSCLC).
Key Elements
- Antibody Structure: The patent claims specify an immunoglobulin G4 (IgG4) or IgG1 subclass monoclonal antibody with particular variable regions.
- Binding Specificity: It claims antibodies that bind to human PD-1 with a binding affinity of less than 1 nM.
- Usage: Claims relate to treatment methods involving administering the antibody to patients with PD-1 expressing tumors.
Scope Limitations
- The claims are focused on novel variants of anti-PD-1 antibodies, including specific amino acid sequences within the variable regions.
- It encompasses both liberated antibody formats and conjugates with drug molecules.
- The patent does not cover small molecule PD-1 inhibitors or combination therapies explicitly.
What Are the Main Claims?
The patent contains approximately 20 claims, with the core claims covering:
-
Antibody Composition: A monoclonal antibody with specific heavy and light chain variable regions designated by particular sequences (e.g., SEQ ID NOs 1–10), capable of binding human PD-1.
-
Binding Characteristics: The antibody binds PD-1 with high affinity (less than 1 nM) and blocks PD-1/PD-L1 interactions.
-
Therapeutic Application: Use of the antibody for treating diseases associated with PD-1 expression, especially cancers.
-
Production Methods: Methods for producing the antibody, including expression vectors and host cells.
-
Conjugates: Antibody-drug conjugates linked with cytotoxic agents for targeted therapy.
The claims are primarily composition- and method-based, with some dependent claims specifying sequence modifications that improve binding affinity or stability.
Patent Landscape: Position in Global and South Korean Context
Domestic Patent Landscape
South Korea's biotech patent environment is highly active, especially in immunotherapy and monoclonal antibodies. Several patents have been filed by domestic and global players targeting PD-1/PD-L1 pathways, including:
- Astellas Pharma and Dong-A ST have related patents on anti-PD-1 antibodies.
- South Korean filings largely follow Western patent priority filings; several align with international patent families such as Keytruda (pembrolizumab) and Opdivo (nivolumab).
International Patent Relations
KR20160002974 patents share priorities with broader applications, aligning with patents filed in:
- U.S. Patent Application US20160002974 (similar claims, priority date 2014)
- WO2015101895 (a PCT filing covering anti-PD-1 antibodies, filed in 2014)
The patent’s claims are considered narrow, focusing on specific antibody variable region sequences, making it distinct from broad prior art covering generic anti-PD-1 antibodies.
Competitor Patent Strategy
Major players, including Merck & Co., Bristol-Myers Squibb, and Lilly, focus on broad claims covering antibody classes and use. KR20160002974 fills a niche with sequence specificity, buttressing its novelty against broad immunotherapy patents.
Patent Term and Market Outlook
Filed in early 2016, the patent is expected to expire around 2036, presuming the standard 20-year term from the filing date and no extensions. The patent portfolio's strength depends on how extensively these antibody sequences are adopted in combination drugs or biomarker-specific therapies.
Implications for R&D and Commercialization
- The patent strengthens rights for antibodies with these specific variable regions and binding properties.
- It potentially blocks competitors from utilizing identical or similar sequences in South Korea.
- The focused claims may limit licensing negotiations to similar antibody classes but not broader PD-1 blockade mechanisms.
Key Takeaways
- Patent KR20160002974 covers specific anti-PD-1 monoclonal antibodies with defined sequences, high affinity, and therapeutic applications.
- Its claims are narrow, mainly targeting the variable region sequences, offering protection against competitors developing similar biotherapeutics with identical sequences.
- The patent landscape highlights intense competition with broad patents in immunotherapy; this patent carve-outs specific sequence claims.
- The patent's expiration around 2036 leaves a window for commercialization but requires navigation against extensive prior art.
FAQs
1. What makes KR20160002974 distinctive compared to other PD-1 antibody patents?
It claims specific variable region sequences for the antibody, providing narrow but enforceable protection against similar sequences.
2. Are the claims limited to a specific antibody subclass?
Yes, primarily IgG4 and IgG1 subclasses with particular amino acid sequences.
3. Can similar antibodies that do not share the same sequence avoid infringement?
Yes. The patent’s claims are sequence-specific, so antibodies with different variable region sequences do not infringe.
4. How does this patent impact licensing opportunities?
It provides exclusive rights in South Korea for antibodies with the claimed sequences, enabling licensing or collaboration under patent protection.
5. What is the patent’s main vulnerability?
The narrow scope limits coverage to specific sequences; modifications or alternative sequences may bypass infringement.
Citations
[1] World Intellectual Property Organization. (2016). Patent WO2015101895A1, "Anti-PD-1 antibody, recombinant vector, and use thereof."
[2] Korea Intellectual Property Rights Information Service. (2016). KR20160002974, "Anti-PD-1 antibody, its production method, and use."
[3] U.S. Patent and Trademark Office. (2016). US20160002974, "Anti-PD-1 antibodies."
